# A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

> **NCT03375203** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 365 (actual)

## Conditions studied

- Insomnia Disorders

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-42847922, 5 mg
- **DRUG:** JNJ-42847922, 10 mg
- **DRUG:** JNJ-42847922, 20 mg
- **DRUG:** Zolpidem

## Key facts

- **NCT ID:** NCT03375203
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-23
- **Primary completion:** 2019-04-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375203, "A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03375203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*